

Table S1 Summarized characteristics of published Mesonephric adenocarcinomas and Mesonephric-like adenocarcinomas arising from the uterine body

Year	Age	Symptom	Ca125	Sizecm	Stage	D&C	Location	IHC		operation	mesonephric remnant	Post operation therapy	OS(month)	Current status	Met
								Positive	Negative						
1995 ^[31]	58	pollakiuria	NL	14	IB	NA	Myometrium	CAM PKK-1 EMA	CEA vimentin	TH+BSO	cervix	CT	9	DOD	Lung
2001 ^[32]	33	Vaginal Bleeding	elevated	7	NA	NA	Myometrium	CD10 CK7 EMA	ER,PR P53	TH+BSO+PLND	None	RT	8	NED	None
2003 ^[33]	33	Vaginal Bleeding	elevated	8	IB	NA	Myometrium	CD10 CK7 Vimentin	ER,PR P53 CEA	TH+BSO+PLND+PALND	None	CT+RT	22	AWD	Lung
2004 ^[4]	37	Vaginal Bleeding	NA	3.5	IB	MNAC	Endometrium Myometrium Involved	calretinin CD10	NA	TH+BSO	None	None	45	NED	None
2006 ^[34]	81	Vaginal Bleeding	elevated	3.7	IB	MNAC	Endometrium Myometrium Involved	Vimentin calretinin EMA	ER,PR, CD10 CEA	TH+BSO+PLND+PALND+OMT	None	None	9	NED	None
2008 ^[35]	73	NA	NL	7.5	IVB	NA	Endometrium Myometrium Involved	calretinin CD10	ER,PR P53	TH+BSO	None	CT	28	AWD	Lung
2014 ^[36]	55	Vaginal Bleeding	NA	3.5	IB	MNAC	Myometrium	CD10 Vimentin calretinin EMA	ER,PR	TH+BSO+PLND	None	None	7	NED	None
2014 ^[36]	62	Vaginal Bleeding	NA	8.0	IB	MNAC	Endometrium Myometrium Involved	CD10 Vimentin calretinin EMA	ER,PR	TH+BSO+PLND	None	None	1	NED	None
2016 ^[37]	66	Vaginal Bleeding	NL	2.7	IB	EC	Endometrium Myometrium Involved	EMA CK7 PAX2 PAX8 TTF-1 CD10 vimentin	ER,PR AR,p53 calretinin CEA α-inhibin	TH+BSO+PLND	None	None	2	NED	None
2016(7cases) ^[21]	NA	NA	NA	NA	IA IA IB II II IIIC IV	NA	Endometrium Myometrium involved	CK7 PAX8 TTF1 CD10 P53 GATA3, calretinin EMA	ER,PR	NA	None	NA	NA	NA	NA
2016 ^[49]	55	Vaginal bleeding	elevated	3.5	II	AC	myometrium	calretinin CD10	ER,PR	TH+BSO+PLND	None	CT	12	DOD	Lymph node
2016 ^[49]	62	Vaginal bleeding	NL	5.8	IIIC	MNAC	Endometrium Myometrium involved	CD10 Vimentin P16	calretinin ER,PR P53	TH+BSO+PLND	None	CT+RT	16	NED	Lymph node
2017 ^[38]	61	None	elevated	8	IIB	NA	Myometrium	CK7 PAX8 CD10 calretinin GATA3 TTF1 Vimentin	ER,PR P53	TH+BSO	None	CT	9	NED	None
2019 ^[39]	58	Vaginal bleeding	elevated	2.3	IIIB	EC	endometrium	GATA3 PTEN CD10 CK7 calretinin	ER,PR P53,P16	TH+BSO+PLND+PALND	None	CT+RT	56	AWD	Lung
2019 ^[39]	55	Vaginal bleeding	NL	7.4	IVB	NA	Endometrium Myometrim involved	GATA3 PTEN CD10 CK7 calretinin	ER,PR P53,P16	TH+BSO	None	CT+RT	21	AWD	Lung
2019 ^[39]	54	Vaginal bleeding	NL	4.3	IIIB	NA	Endometrium	GATA3 PTEN CD10 CK7 calretinin	ER,PR P53,P16	TH+BSO	None	CT+RT	20	AWD	Lung
2019 ^[39]	60	Vaginal bleeding	NL	4.1	IA	CS	Endometrium	GATA3 PTEN CD10 CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	CT	14	AWD	Lung
2019 ^[39]	53	Vaginal bleeding	NL	2.7	IA	EC	Endometrium Myometrim involved	GATA3 PTEN CD10 CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	None	12	NED	None
2019 ^[39]	57	Vaginal bleeding	NL	5.3	IIIC	EC	Endometrium Myometrim involved	GATA3 PTEN CD10 CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	CT	13	AWD	Lung
2019 ^[39]	70	Vaginal bleeding	NL	2.6	IB	EC	myometrium	GATA3 PTEN CD10 CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	RT	10	NED	None
2019 ^[39]	61	Vaginal bleeding	NL	2.2	IB	MNAC	Endometrium Myometrim involved	GATA3 PAX2 PTEN CD10 CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	CT	7	NED	None
2019 ^[39]	65	Vaginal bleeding	NL	3.7	IB	MNAC	Endometrium Myometrim involved	GATA3 PTEN CD10 CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	None	6	NED	None
2019 ^[39]	52	Abdominal pain	elevated	4.8	IIIC	NA	Endometrium	GATA3 PTEN CD10、CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	CT+RT	3	NED	Lymph node
2019 ^[39]	59	Vaginal bleeding	NL	1.5	IA	EC	Endometrium Myometrim involved	GATA3 PTEN CD10 CK7	ER,PR P53,P16 calretinin	TH+BSO+PLND+PALND	None	None	11	NED	None
2018 ^[45]	65	NA	NA	NA	IVB	NA	NA	GATA3 TTF1 PAX8 ER CD10	Calretinin	NA	None	NA	NA	NA	NA

Table S1 (continued)

Table S1 (continued)

Year	Age	Symptom	Ca125	Sizecm	Stage	D&C	Location	IHC		operation	mesonephric remnant	Post operation therapy	OS(month)	Current status	Met
								Positive	Negative						
2018 ^[49]	31	NA	NA	NA	IIIA	NA	NA	GATA3 TTF1 PAX8 CD10	ER Calretinin	NA	None	NA	NA	NA	NA
2018 ^[49]	75	NA	NA	NA	IB	NA	NA	GATA3 TTF1 PAX8 CD10	ER calretinin	NA	None	NA	NA	NA	NA
2018 ^[49]	91	NA	NA	NA	IIIA	NA	NA	GATA3 TTF1 PAX8 ER	CD10 Calretinin	NA	None	NA	NA	NA	NA
2018 ^[41]	71	NA	NA	3.0	II	NA	Endometrium Myometrium involved	GATA3 TTF1 PAX8 ER	PR β-catenin	TH+BSO	None	NA	NA	NA	NA
2018 ^[42]	63	Vaginal bleeding	NA	9.0	IB	EC	Endometrium Myometrium involved	AE1/3 GATA3 PAX8 calretininWT-1 CD10	ER,PR	TH+BSO+PLND+PALND+OMB	None	RT	30	NED	
2018 ^[42]	57	Abdominal pain	elevated	6.5	IIIA	EC	Myometrium	CK7 PAX8 GATA3 vimentin	ER,PR Napsin TTF-1 WT-1 P53 PTEN CK20 P16	TH+BSO+PLND+OMB	None	CT	NA	NA	
2019 ^[40]	32	Vaginal bleeding	NL	4	IA	EC	Endometrium Myometrium involved	TTF-1 GATA3 CD10 P53 CA125 CK7 P16	ER,PR,AR calretininHNF-1 β-napsin WT-1	TH+BSO+OMT	None	None	5	NED	None
2019 ^[50]	65	NA	NA	NA	IA	NA	Endometrium	CCD10 GATA3	ER,PR WT-1	NA	NA	NA	NA	NA	NA
2019 ^[50]	58	NA	NA	NA	IA	NA	Endometrium	EMA PAX8 vimentin, calretininHMGGA2 CA125		NA	NA	NA	NA	NA	NA
2019 ^[50]	77	NA	NA	NA	IB	NA	Endometrium			NA	NA	NA	NA	NA	NA
2019 ^[50]	56	NA	NA	NA	IIIB	NA	Endometrium			NA	NA	NA	NA	NA	NA
2019 ^[44]	64	NA	NA	NA	IB	CS	Endometrium Myometrium involved	TTF-1 GATA3 CD10 PAX8 ER	PR,P53	TH+BSO+PLND+OMT	NA	NA	150	AWD	Lung
2019 ^[44]	57	NA	NA	NA	IA	EC	Endometrium	TTF-1 CD10 ER,PR	GATA3 p53	NA	NA	NA	19	NED	None
2019 ^[44]	58	NA	NA	NA	IVB	EC	NA	p16 TTF-1 CD10	ER, PR GATA3 P53	NA	NA	NA	30	AWD	NA
2019 ^[44]	62	NA	NA	NA	IIIC	EC	NA	PAX8 TTF-1	ER, PR p53,	NA	NA	NA	100	DOD	Lung
2020 ^[43]	74	Vaginal bleeding	NA	5.5	IIA	NA	Endometrium	TTF-1 WT-1 P53 P16 CD10	ER, PR GATA3	NA	NA	NA	NA	NA	NA
2020 ^[43]	54		NA	4	IB	NA	Endometrium	TTF-1 WT-1 P53 P16	ER, PR	NA	NA	NA	NA	NA	NA
2020 ^[43]	64		NA	3.2	IB	NA	Endometrium	TTF-1 WT-1 P53 P16	ER, PR	NA	NA	NA	NA	NA	NA
2020 ^[43]	61		NA	4.7	II	NA	Endometrium	TTF-1 WT-1 P53 P16 CD10	ER, PR GATA3	NA	NA	NA	NA	NA	NA
Present study	67	Vaginal bleeding	NL	9	IVB	No	Endometrium Myometrium involved	PTEN CD10 TTF-1 PAX8, p16 P53 GATA3	ER,PR,ARWT-1 HNF1-B	TH+BSO+PLND+PALND+OMT+APD	None	CT	3	AWD	lung
Present study	55	Vaginal bleeding	elevated	11	IVB	AC	myometrium	EMA CK7 CD10 TTF Pax-2 Pax-8	PTEN ER,PR P16, Vimentin GATA3	TH+BSO	yes	CT	4	AWD	lung
Present study	75	None	NL	5	IVB	None	myometrium	EMA CK7 Pax-8 Pax-2 CD-10, TTF-1 P16	ER,PR CK-20 AR CEA	TH	Yes	CT	17	NED	None

Abbreviation: IHC:immunohistochemistry; NL:normal level; NA:not available; TH:total hysterectomy; BSO:bilateral salpingo-oophorectomy; PLND:pelvic lymphonode dissection;PALND:para-aorta lymphonode dissection;OMT:omentectomy;OMB:Omental biopsy;APD:appendectomy; EC:endometrioid carcinoma;MNAC: mesonephric adenocarcinoma;CS:carcinosarcoma;AWD:alive with disease;DOD:died of disease; ND: not done; NED: no evidence of disease.;CT:chemotherapy;RT:Radiotherapy;Met:metastasis;